Skip to main content
. Author manuscript; available in PMC: 2019 Apr 5.
Published in final edited form as: Nanoscale. 2018 Apr 5;10(14):6712–6723. doi: 10.1039/c8nr01106k

Figure 6.

Figure 6

a) GSH/GSSG ratio for no treatment control, NP78.9-EGF, NP40.4-EGF NP21.5-EGF, NP78.9-EGF + AG1478, NP78.9-EGF + NAC, NP78.9-EGF + trolox, NP78.9-EGF + tempol. b) Apoptosis enhancement for NP78.9-EGF, NP78.9-EGF + Ag1478, NP78.9-EGF + trolox, NP78.9-EGF + tempol. All presented data were recorded from three independent experiments. Error bars show standard deviations. Significance was evaluated relative to the no treatment control (a) or NP78.9-EGF (b). **p < 0.01; *p < 0.05.